RecruitingPHASE1, PHASE2NCT06810778
Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Studying T-cell prolymphocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Jonsson Comprehensive Cancer Center
- Intervention
- Duvelisib(drug)
- Enrollment
- 12 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2031
Study locations (1)
- David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, California, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06810778 on ClinicalTrials.govOther trials for T-cell prolymphocytic leukemia
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE1NCT04629729FT819 in Subjects With B-cell MalignanciesFate Therapeutics
- ACTIVE NOT RECRUITINGPHASE1NCT04684563huCART19-IL18 in CD19+ CancersUniversity of Pennsylvania
- ACTIVE NOT RECRUITINGPHASE1NCT04732845Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid MalignanciesBenjamin Tomlinson
- RECRUITINGNCT04411043Observatory of Prolymphocytic Leukemia TFrench Innovative Leukemia Organisation
- ACTIVE NOT RECRUITINGPHASE1NCT00586391CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLLBaylor College of Medicine